.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Teva
Julphar
Johnson and Johnson
Federal Trade Commission
US Department of Justice
AstraZeneca
McKesson
Baxter
Daiichi Sankyo

Generated: December 16, 2017

DrugPatentWatch Database Preview

Oxaliplatin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for oxaliplatin and what is the scope of oxaliplatin freedom to operate?

Oxaliplatin
is the generic ingredient in two branded drugs marketed by Sanofi Aventis Us, Accord Hlthcare, Actavis Totowa, Cipla Ltd, Fresenius Kabi Oncol, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira Inc, Hospira Worldwide, Jiangsu Hengrui Med, Luitpold Pharms Inc, Mylan Labs Ltd, Qilu Pharm Co Ltd, Sandoz, Sandoz Inc, Sanja Pharms Co, Sun Pharma Global, and Teva Pharms, and is included in twenty-six NDAs. There is one patent protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Oxaliplatin has five patent family members in four countries.

There are twenty-six drug master file entries for oxaliplatin. Twenty-two suppliers are listed for this compound. There are six tentative approvals for this compound.

Pharmacology for oxaliplatin

Tentative approvals for OXALIPLATIN

Applicant Application No. Strength Dosage Form
u► Subscribe5MG/MLINJECTABLE; INJECTION
u► Subscribe100MG/20ML (5MG/ML)INJECTABLE;IV (INFUSION)
u► Subscribe50MG/10ML (5MG/ML)INJECTABLE;IV (INFUSION)
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord HlthcareOXALIPLATINoxaliplatinINJECTABLE;IV (INFUSION)207474-003Mar 21, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Actavis TotowaOXALIPLATINoxaliplatinINJECTABLE;IV (INFUSION)078803-001Aug 8, 2012APRXNoNo► Subscribe► Subscribe► Subscribe
Accord HlthcareOXALIPLATINoxaliplatinINJECTABLE;IV (INFUSION)207474-002Mar 21, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharma GlobalOXALIPLATINoxaliplatinINJECTABLE;IV (INFUSION)078818-001Aug 7, 2009APRXNoYes► Subscribe► Subscribe► Subscribe
Accord HlthcareOXALIPLATINoxaliplatinINJECTABLE;IV (INFUSION)207474-001Mar 21, 2017APRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Labs LtdOXALIPLATINoxaliplatinINJECTABLE;IV (INFUSION)200979-002Aug 8, 2012APRXNoNo► Subscribe► Subscribe► Subscribe
Actavis TotowaOXALIPLATINoxaliplatinINJECTABLE;IV (INFUSION)078803-002Aug 8, 2012APRXNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021759-003Nov 17, 2006DISCNYesNo► Subscribe► SubscribeY► Subscribe
Hospira IncOXALIPLATINoxaliplatinINJECTABLE;IV (INFUSION)078815-001Sep 30, 2009APRXNoNo► Subscribe► Subscribe► Subscribe
Teva PharmsOXALIPLATINoxaliplatinINJECTABLE;IV (INFUSION)022160-002Aug 7, 2009APRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: oxaliplatin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021759-003Nov 17, 2006► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021759-001Jan 31, 2005► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021759-003Nov 17, 2006► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021759-002Jan 31, 2005► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021492-001Aug 9, 2002► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021492-002Aug 9, 2002► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021759-003Nov 17, 2006► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021759-002Jan 31, 2005► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021492-002Aug 9, 2002► Subscribe► Subscribe
Sanofi Aventis UsELOXATINoxaliplatinINJECTABLE;IV (INFUSION)021759-001Jan 31, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: oxaliplatin

Country Document Number Estimated Expiration
Japan3025602► Subscribe
JapanH06329692► Subscribe
Spain2167328► Subscribe
Germany69331048► Subscribe
European Patent Office0625523► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Farmers Insurance
Accenture
QuintilesIMS
Healthtrust
Fuji
Novartis
US Army
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot